Top Page
Physiomics
(LSE:PYC)
Physiomics (PYC) vs. S&P 500 (SPY)
Physiomics Business Overview & Revenue Model
Physiomics Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 543.25K | 597.35K | 830.27K | 702.31K | 799.05K | Gross Profit |
| -677.43K | -581.62K | -429.01K | -365.79K | -177.15K | EBIT |
| -670.82K | -581.62K | -429.01K | -365.78K | -177.15K | EBITDA |
| -659.80K | -561.57K | -347.84K | -324.52K | -124.71K | Net Income Common Stockholders |
| -609.35K | -477.26K | -253.14K | -215.83K | -64.42K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 191.07K | 416.59K | 687.67K | 1.04M | 1.05M | Total Assets |
| 422.60K | 674.39K | 1.12M | 1.32M | 1.45M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -191.07K | -416.59K | -687.67K | -1.04M | -1.05M | Total Liabilities |
| 140.08K | 142.67K | 140.61K | 157.57K | 131.52K | Stockholders Equity |
| 282.53K | 531.72K | 974.81K | 1.17M | 1.31M |
| Cash Flow | Free Cash Flow | |||
| -565.44K | -271.50K | -358.62K | -48.65K | -120.78K | Operating Cash Flow |
| -548.13K | -264.86K | -349.25K | -32.50K | -115.69K | Investing Cash Flow |
| -15.21K | -6.22K | -9.37K | -16.15K | -5.09K | Financing Cash Flow |
| 337.83K | 0.00 | 2.85K | 44.24K | 763.28K |
Physiomics Technical Analysis
Physiomics Peers Comparison
Physiomics Corporate Events
Physiomics plc reported interim financial results for the six-month period ending December 31, 2024, showing a slight decrease in revenue and an increase in operating loss compared to the previous year. Despite these financial challenges, the company has established a strong pipeline with new contracts and expanded its service offerings, including the launch of a Biostatistics service line and the development of Personalized Medicine Dosing Software. The company completed a successful fundraising effort, enhancing its cash position, and is on track to meet market expectations for the year, driven by a robust second half and strategic growth initiatives.
Physiomics plc announced it will release its interim results on March 6, 2025, followed by a live investor presentation on March 10, 2025. This presentation, led by CEO Peter Sargent and Chairman Jim Millen, will be open to existing and potential shareholders, providing an opportunity to discuss the interim results and broader business aspects. This initiative reflects Physiomics’ commitment to transparency and engagement with its stakeholders, potentially enhancing its industry positioning and investor relations.
Physiomics PLC has announced a change in major holdings, indicating a shift in the company’s shareholder structure. Ryan Mancrief has sold his holdings at Barclays Investment Solutions Limited, now holding 14,234,711 shares in a nominee account at AJ Bell plc, which represents 4.6947% of the company’s issued share capital. This change reflects a decrease from a previous position of 8.5127% and may impact the company’s voting dynamics and influence among stakeholders.
Physiomics plc announced the successful completion of its WRAP Retail Offer, raising £70,000, which combined with a previous placing, totals £500,000 in gross proceeds. The funds will support the company’s growth, including recruitment for its consulting services, investment in business development, and the expansion of its personalized medicine tools, signifying an effort to bolster its industry position and service offerings.
Physiomics plc has announced a retail offer via the Winterflood Retail Access Platform to raise up to £70,000 through the issuance of new ordinary shares. This offer is part of a broader strategy to raise approximately £500,000 through a separate placing of new shares. The funds raised will support the company’s ongoing operations and strategic initiatives. The offer is targeted exclusively at existing retail shareholders in the UK, emphasizing the company’s commitment to its retail shareholder base. The offer is not contingent upon the completion of the separate placing, ensuring flexibility in capital acquisition. This initiative reflects Physiomics’ strategic approach to strengthening its financial position and enhancing shareholder value.
Physiomics plc has successfully completed a £430,000 placing to fund growth opportunities, issuing 86,000,000 new ordinary shares at a 37.5% discount. The company is also launching a retail offer to raise an additional £70,000. The funds will support the recruitment of technical staff, business development, and strategic growth in their consulting services. The company has made progress with new contract awards and publications, and aims to further its personalized medicine tools in collaboration with DoseMe. Recent achievements include contract wins and high-profile collaborations, positioning the company for continued growth and new business opportunities in the biotech and pharma sectors.
Physiomics plc announced that it is performing in line with market expectations for the fiscal year ending June 2025, with anticipated income reflecting signed contracts and a slight reduction in expected losses due to improved operational efficiencies and maintained day rates with key customers. The company is in discussions for additional contracts but cannot guarantee they will be finalized within the current fiscal year. Interim results for the six months ending December 2024 are expected to be reported in early March 2025.
Physiomics plc announced the joint publication of a peer-reviewed article with Merck KGaA, showcasing a mathematical model to optimize combination oncology therapies. The publication highlights how Physiomics’ Virtual Tumour platform accelerates drug development by predicting effective experimental permutations, mitigating costs, and informing clinical trial designs. This collaboration underscores the company’s influential role in the development of innovative oncology treatments and its strong, longstanding partnership with Merck KGaA.
Physiomics PLC has announced a significant change in its voting rights structure following the acquisition of shares by Ryan Mancrief. The notification reveals that Mr. Mancrief now holds an 8.5127% voting rights stake in the company, through shares held via AJ Bell plc and Barclays Investment Solutions Limited. This development could potentially influence company decisions and strategic directions, impacting stakeholders and the company’s positioning within the industry.
Physiomics plc announced a joint publication with Astellas Pharma Inc. in the journal ‘CPT: Pharmacometrics & Systems Pharmacology,’ detailing a study on optimizing treatment regimens for an oncolytic virus combined with Pembrolizumab. The study highlights the importance of dose and scheduling optimization in immunotherapy, a promising cancer treatment approach. The use of Physiomics’ Virtual Tumour platform demonstrates their capability to assist in developing innovative therapies by accelerating and de-risking the drug development process, reinforcing their position as a valuable partner for pharmaceutical companies in developing advanced cancer treatments.
Physiomics plc announced that its Innovate UK funded project, PREDICT-ONC, has received both regulatory and ethical approval. This project aims to further develop their personalized dosing software which assists clinicians in optimizing chemotherapy dosing for individual patients. The software, initially designed for cancer chemotherapy dosing, has shown potential in predicting GCSF dosing to alleviate chemotherapy-induced neutropenia. Despite delays in the trial start, which were beyond the company’s control, recruitment is set to begin imminently, with minimal impact on the overall timeline anticipated.
Physiomics plc has announced a new contract with Numab Therapeutics AG, involving the use of Pharmacokinetic-Pharmacodynamic modelling to enhance a key asset in Numab’s pipeline. This collaboration underscores Physiomics’ expertise in modelling and simulation to expedite therapeutic development, reinforcing its position as a valuable partner in the drug development process.